Supplemental Table 4. Surgery characteristics, neuromuscular blocker use, reversal use, and post-surgery outcome data from electronically searched medical charts (n= 20,181). Only data from the implementation ramp up period is shown. Median [25th, 75th percentile] for continuous variables; percent for categorical variables.

|  |  |
| --- | --- |
|  | Implementation ramp up 10/01/2018 - 1/31/2020 |
| Surgeries, number | 6990 |
| Neuromuscular blocking agent, number (%) |
|  Cisatracurium | 152/6990 (2%) |
|  Rocuronium | 6838/6990 (98%) |
| Reversal Type, number (%) |
|  Neostigmine | 3166/6990 (45%) |
|  Sugammadex | 3366/6990 (48%) |
|  No reversal | 458/6990 (7%) |
| Surgery Duration, minutes, median [25th, 75th percentile] | 104 [63,165] |
| PACU ready for discharge, minutes, median [25th, 75th percentile] | 79 [57,110] |
| PACU to Transfer, minutes, median [25th, 75th percentile] | 96 [71,132] |
| Postoperative Pulmonary Complications, number (%) |
|  Overall | 59/6990 (0.8%) |
|  Inpatient | 52/2995 (1.7%) |
|  Observation | 0/31 (0%) |
|  Outpatient | 7/3964 (0.2%) |
| Hospital LOS, days, median [25th, 75th percentile] |  |
|  Inpatient | 3 [1,4] |
|  Observation | 1 [1,2] |
|  Outpatient | 0 [0,1] |
| Discharge Disposition, number (%) |
|  Home | 6624/6990 (95%) |
|  Died | 8/6990 (0.1%) |
| Inpatients readmit to hospital, number (%) | 181/2993 (6%) |